Motixafortide + Natalizumab for Sickle Cell Disease

Recruiting in Palo Alto (17 mi)

Overseen by Zachary D Crees, M.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Washington University School of Medicine

Must not be taking: Immunosuppressants, TNF-α inhibitors

Disqualifiers: Prior HCT, Gene therapy, Infections, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing two drugs, motixafortide and natalizumab, to help patients with sickle cell disease. These drugs aim to move more stem cells from the bone marrow into the blood, making it easier to collect them for gene therapy. Natalizumab is also used to treat multiple sclerosis.

Do I need to stop my current medications to join the trial?

Yes, you need to stop taking hydroxyurea, voxelotor, and/or crizanlizumab for at least 60 days before mobilization, and iron chelation for at least 7 days before mobilization.

What data supports the idea that Motixafortide + Natalizumab for Sickle Cell Disease is an effective treatment?

The available research does not provide specific data on the effectiveness of Motixafortide + Natalizumab for Sickle Cell Disease. The studies mentioned focus on other conditions and treatments, such as autoimmune hemolytic anemia, hairy cell leukemia, idiopathic myelofibrosis, acute promyelocytic leukemia, and cancer patients undergoing stem cell collection. Therefore, there is no direct evidence from the provided information to support the effectiveness of Motixafortide + Natalizumab for Sickle Cell Disease. ^{1 2 3 4 5}

What safety data exists for the treatment of Motixafortide + Natalizumab for Sickle Cell Disease?

The safety data for Motixafortide, a CXCR4 inhibitor, shows it is safe and well-tolerated when used with G-CSF for hematopoietic stem cell mobilization, with common adverse events being mild injection site reactions. Motixafortide is being developed for sickle cell disease, but specific safety data for its combination with Natalizumab in this context is not provided in the available research. However, Motixafortide has been shown to be a promising agent for stem cell mobilization in other conditions, and its safety profile in these contexts is favorable. ^{6 7 8 9 10}

Is the drug Motixafortide a promising treatment for Sickle Cell Disease?

Yes, Motixafortide is a promising drug for Sickle Cell Disease because it helps collect important stem cells needed for treatments. It has been shown to work well in other conditions and is being developed for Sickle Cell Disease, which could help patients who need stem cell-based therapies. ^{6 9 10 11 12}

Research Team

Zachary D Crees, M.D.

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

Adults aged 18-40 with sickle cell disease (hemoglobin SS or Sβ0 genotype), able to pause certain medications, and have specific health criteria like a platelet count of at least 75,000/uL. They must not be pregnant, agree to use contraception during the study and for three months after, and cannot have had previous gene therapies or certain immunosuppressants.

Inclusion Criteria

My bone marrow and organs are functioning normally.

Left ventricular ejection fraction (LVEF) ≥ 45%

AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN at time of screening

Exclusion Criteria

Patient may not have a history of significant alloantibodies which, in the opinion of the treating physician and study investigator, significantly increase the risk of participation in this clinical trial

I am currently taking drugs that suppress my immune system.

I have never had a stem cell transplant or gene therapy.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Phase 1

Participants receive a single subcutaneous injection of motixafortide, followed by leukapheresis

8 weeks

1 visit (in-person) for injection and leukapheresis, followed by monitoring

Treatment Phase 2

Participants receive a single IV infusion of natalizumab, followed by a subcutaneous injection of motixafortide, then leukapheresis

8 weeks

1 visit (in-person) for infusion and injection, followed by leukapheresis and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Leukapheresis (Other)
• Motixafortide (Other)
• Natalizumab (Monoclonal Antibodies)

Trial Overview The trial is testing Motixafortide and Natalizumab's ability to mobilize hematopoietic stem cells in preparation for gene therapy in sickle cell disease patients. It aims to see if these drugs can safely increase the number of stem cells available for treatment without unacceptable risks.

Participant Groups

Group I: Motixafortide followed by Motixafortide + Natalizumab Experimental Treatment 3 Interventions

* Consenting and eligible patients will receive a single subcutaneous injection of motixafortide, followed by leukapheresis. Patient will then be followed for 8 weeks for adverse event monitoring. * Following the 8-week monitoring period, patients will receive a single IV infusion natalizumab, then approximately 32 hours later, a single subcutaneous injection of motixafortide, followed by leukapheresis. Patients will then be followed for 8 weeks for adverse event monitoring.

Leukapheresis is already approved in Canada for the following indications:

Approved in Canada as Leukapheresis for:

• Acute myeloid leukemia (AML)
• Acute lymphoblastic leukemia (ALL)
• Chronic myeloid leukemia (CML)
• Hyperviscosity syndrome

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+

David H. Perlmutter

Washington University School of Medicine

Chief Executive Officer since 2015

MD from Washington University School of Medicine

Paul Scheel

Washington University School of Medicine

Chief Medical Officer since 2022

MD from Washington University School of Medicine

Biogen

Industry Sponsor

Trials

655

Recruited

468,000+

Daniel Quirk

Biogen

Chief Medical Officer

MD

Christopher A. Viehbacher

Biogen

Chief Executive Officer since 2022

Graduated from Queen's University, Kingston, Ontario, Canada

BioLineRx, Ltd.

Industry Sponsor

Trials

24

Recruited

2,200+

Findings from Research

In a study of 47 patients with autoimmune hemolytic anemia (AIHA) who had inadequate bone marrow response, treatment with recombinant erythropoietin (rEPO) led to a significant increase in hemoglobin levels, with 91% of patients showing a response by 12 months.

rEPO treatment also reduced the need for blood transfusions from 30% to less than 10% within 15 days, demonstrating its efficacy as an adjunct therapy alongside standard immunosuppressive treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis. Fattizzo, B., Pedone, GL., Brambilla, C., et al.[2023]

Therapeutic leukapheresis in three patients with advanced hairy cell leukemia led to significant and lasting clinical and hematologic improvements, with benefits observed for over 23 to 26 months.

In contrast, plasmapheresis did not produce any noticeable therapeutic effects in two similar patients, suggesting that leukapheresis may effectively remove inhibitory factors affecting blood cell production.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Therapeutic leukapheresis in hairy cell leukemia. Mielke, CH., Dobbs, CE., Winkler, CF., et al.[2007]

A patient with idiopathic myelofibrosis was successfully treated with HLA-identical platelet apheresis concentrates, maintaining platelet counts between 20 and 30 x 10(9)/L using crossmatched negative products.

Despite initial treatment, the patient developed refractoriness to haploidentical sibling platelets, and attempts to absorb platelet antibodies using Protein A columns were ineffective, indicating a complex immune mechanism at play.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A case of idiopathic myelofibrosis with alloimmunization to HLA-identical platelet transfusions not responsive to antibody absorption over protein-A columns. Menicucci, A., Di Pietro, G., Venturini, S., et al.[2019]

In a study of 242 patients with acute promyelocytic leukaemia (APL), those with hyperleucocytosis (high white blood cell count) had significantly lower complete remission rates (69% vs. 88%) and higher 4-week mortality (24% vs. 9%) compared to those without hyperleucocytosis.

Treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) combined with cytotoxic therapy resulted in a 100% complete remission rate and overall survival for hyperleucocytosis patients, outperforming non-ATRA/ATO treatments, which had much lower success rates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Daver, N., Kantarjian, H., Marcucci, G., et al.[2021]

In a study of 27 cancer patients undergoing stem cell collection after high-dose cyclophosphamide treatment, those who received granulocyte-macrophage colony stimulating factor (rhGM-CSF) showed significantly higher yields of mononuclear cells and granulocyte-macrophage colony forming units (CFU-GM) during leukapheresis.

The use of rhGM-CSF not only accelerated hematopoietic recovery but also allowed for more efficient collection of stem cells, with procedures being well tolerated and only minor side effects reported.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Role of recombinant human granulocyte-macrophage colony stimulating factor for large scale collection of peripheral blood stem cells for autologous transplantation. Ravagnani, F., Bregni, M., Siena, S., et al.[2006]

Motixafortide, a selective CXCR4 inhibitor, was approved in the USA on September 11, 2023, for mobilizing hematopoietic stem cells (HSCs) in combination with filgrastim for patients with multiple myeloma, marking a significant advancement in stem cell transplantation.

The drug has also received Orphan Drug Designation for treating pancreatic cancer and acute myeloid leukemia, and is being studied for mobilizing CD34+ HSCs for gene therapy in sickle cell disease, indicating its potential in various cancer treatments and therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Motixafortide: First Approval. Hoy, SM.[2023]

A 6-month-old boy with familial erythrophagocytic lymphohistiocytosis successfully underwent allogeneic bone marrow transplantation after achieving remission with Etoposide and prednisone, indicating the effectiveness of this pre-transplant treatment.

The conditioning regimen for the transplant was well tolerated, and the patient has remained in complete remission for over 10 months, demonstrating the potential long-term efficacy of this treatment approach.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Allogeneic Bone Marrow Transplantation for Familial Erythrophagocytic Lymphohistiocytosis, with High Dose VP16-Containing Conditioning Regimen. Todo, S., Fujiwara, F., Ikushima, S., et al.[2019]

In the GENESIS trial involving 122 adult patients with multiple myeloma, the combination of motixafortide and G-CSF significantly improved the collection of CD34+ hematopoietic stem and progenitor cells (HSPCs) for autologous stem cell transplantation, achieving a success rate of 92.5% compared to only 26.2% with placebo plus G-CSF.

Motixafortide was found to be safe and well tolerated, with mostly mild and transient side effects, indicating its potential as an effective and safe option for enhancing HSPC mobilization in patients undergoing treatment for multiple myeloma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Crees, ZD., Rettig, MP., Jayasinghe, RG., et al.[2023]

Motixafortide, a novel CXCR4 inhibitor, shows promise in rapidly mobilizing large numbers of hematopoietic stem and progenitor cells (HSPCs) for transplantation, potentially addressing the limitations of current mobilization regimens that often require multiple days of treatment and can lead to adverse effects.

Unlike granulocyte colony-stimulating factor (G-CSF), which can cause serious complications in certain patient populations, including those with sickle-cell disease, motixafortide preferentially mobilizes more primitive HSPCs and has a longer duration of action, making it a safer and more effective option for HSPC mobilization.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Crees, ZD., Rettig, MP., DiPersio, JF.[2023]

In a six-month study involving 35 subjects with sickle cell disease, elevated blood cell adhesion to P-selectin was significantly associated with vaso-occlusive crisis (VOC) events, indicating its potential as a biomarker for predicting VOC risk.

A combined multimarker risk score using both P-selectin and VCAM-1 was found to be effective in stratifying patients into low, intermediate, and high-risk categories for VOC, which could enhance personalized treatment and optimize healthcare resource allocation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease. Hines, PC., Callaghan, MU., Zaidi, AU., et al.[2023]

In a study of 55 newly diagnosed multiple myeloma patients, single large volume leukapheresis using either G-CSF or G-CSF plus Plerixafor successfully achieved the primary stem cell yield target of ≥2×10^6 cells per kg in all cases.

The procedure was found to be safe and cost-effective, with manageable adverse reactions, and factors such as age and pre-apheresis CD34+ count significantly influenced the stem cell yield.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation. Ray, GK., Jena, RK., Panda, T., et al.[2021]

References

1. United States pubmed.ncbi.nlm.nih.gov

Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Therapeutic leukapheresis in hairy cell leukemia. [2007]

3. England pubmed.ncbi.nlm.nih.gov

A case of idiopathic myelofibrosis with alloimmunization to HLA-identical platelet transfusions not responsive to antibody absorption over protein-A columns. [2019]

4. England pubmed.ncbi.nlm.nih.gov

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. [2021]

5. Italy pubmed.ncbi.nlm.nih.gov

Role of recombinant human granulocyte-macrophage colony stimulating factor for large scale collection of peripheral blood stem cells for autologous transplantation. [2006]

6. New Zealand pubmed.ncbi.nlm.nih.gov

Motixafortide: First Approval. [2023]

7. United States pubmed.ncbi.nlm.nih.gov

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Allogeneic Bone Marrow Transplantation for Familial Erythrophagocytic Lymphohistiocytosis, with High Dose VP16-Containing Conditioning Regimen. [2019]

9. United States pubmed.ncbi.nlm.nih.gov

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. [2023]

10. England pubmed.ncbi.nlm.nih.gov

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. [2023]

11. England pubmed.ncbi.nlm.nih.gov

Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease. [2023]

12. Brazil pubmed.ncbi.nlm.nih.gov

Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation. [2021]